{"id":"cch-administration","safety":{"commonSideEffects":[{"rate":"~50","effect":"Penile hematoma"},{"rate":"~40","effect":"Penile ecchymosis"},{"rate":"~30","effect":"Penile swelling"},{"rate":"~20","effect":"Pain at injection site"},{"rate":null,"effect":"Penile corporal fibrosis"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL965","moleculeType":"Small molecule","molecularWeight":"147.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CCH contains two collagenase enzymes derived from Clostridium histolyticum that enzymatically degrade collagen types I and III, the primary structural components of the fibrotic plaques characteristic of Peyronie's disease. By degrading these plaques through direct enzymatic action, the drug reduces penile curvature and restores normal penile anatomy and function. The enzyme is injected directly into the plaque under ultrasound guidance.","oneSentence":"CCH (collagenase clostridium histolyticum) is an injectable enzyme that breaks down collagen in penile plaques, reducing curvature and improving erectile function in Peyronie's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:25.471Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peyronie's disease with penile curvature deformity"}]},"trialDetails":[{"nctId":"NCT05324748","phase":"PHASE3","title":"Repeated GON Injections in CCH","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-11-07","conditions":"Cluster Headache","enrollment":50},{"nctId":"NCT06169319","phase":"PHASE2","title":"A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2024-01-03","conditions":"Plantar Fasciitis","enrollment":231},{"nctId":"NCT03192020","phase":"PHASE4","title":"Trial Comparing Treatment Strategies in Dupuytren's Contracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tampere University","startDate":"2017-09-15","conditions":"Dupuytren Contracture","enrollment":302},{"nctId":"NCT05419505","phase":"PHASE2","title":"Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2022-06-15","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite","enrollment":91},{"nctId":"NCT06649539","phase":"PHASE4","title":"Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease","status":"RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2024-10-11","conditions":"Peyronie Disease","enrollment":40},{"nctId":"NCT04786106","phase":"PHASE4","title":"Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2020-12-30","conditions":"Peyronie's Disease","enrollment":40},{"nctId":"NCT05108558","phase":"PHASE4","title":"Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2021-09-20","conditions":"Peyronie's Disease","enrollment":40},{"nctId":"NCT05064397","phase":"PHASE3","title":"A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2021-09-17","conditions":"Chronic Cluster Headache","enrollment":131},{"nctId":"NCT04381117","phase":"","title":"Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2020-05-06","conditions":"Edematous Fibrosclerotic Panniculopathy","enrollment":7},{"nctId":"NCT03526549","phase":"PHASE3","title":"Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2018-04-26","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite","enrollment":483},{"nctId":"NCT03632993","phase":"PHASE2","title":"Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2018-09-18","conditions":"Edematous Skin","enrollment":64},{"nctId":"NCT04677712","phase":"PHASE4","title":"Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2020-12-28","conditions":"Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite","enrollment":48},{"nctId":"NCT05309525","phase":"PHASE4","title":"Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females","status":"COMPLETED","sponsor":"Luxurgery","startDate":"2022-04-22","conditions":"Cellulite","enrollment":17},{"nctId":"NCT05249257","phase":"","title":"Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2022-01-25","conditions":"Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy","enrollment":20},{"nctId":"NCT04580303","phase":"PHASE2","title":"CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2020-10-01","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin","enrollment":35},{"nctId":"NCT04236635","phase":"PHASE2","title":"Histopathology Following CCH Injection","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2019-12-20","conditions":"Characteristics of Subcutaneous Tissue","enrollment":10},{"nctId":"NCT04170296","phase":"PHASE3","title":"Real World CCH Study in Adult Females With Cellulite","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2019-11-01","conditions":"Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite","enrollment":153},{"nctId":"NCT04209530","phase":"PHASE2","title":"Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women","status":"TERMINATED","sponsor":"Endo Pharmaceuticals","startDate":"2019-11-20","conditions":"Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)","enrollment":7},{"nctId":"NCT05026216","phase":"PHASE4","title":"To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.","status":"COMPLETED","sponsor":"DMR Research, PLLC","startDate":"2021-03-29","conditions":"Cellulite","enrollment":5},{"nctId":"NCT04449900","phase":"","title":"Quantitative Evaluation of Parafoveal Microvasculature Changes in Eyes With Exudative Circumscribed Choroidal Haemangioma: An Optical Coherence Tomography Angiography Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-03-01","conditions":"Circumscribed Choroidal Haemangioma, Optical Coherence Tomography Angiography, Macular","enrollment":82},{"nctId":"NCT04370652","phase":"","title":"Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-01-01","conditions":"Peyronie Disease","enrollment":156},{"nctId":"NCT02358135","phase":"NA","title":"Collaborative Connected Health (CCH) for PCORI","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-02-02","conditions":"Psoriasis","enrollment":300},{"nctId":"NCT02006719","phase":"PHASE2","title":"Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2013-11","conditions":"Adhesive Capsulitis, Frozen Shoulder","enrollment":322},{"nctId":"NCT02462395","phase":"PHASE2, PHASE3","title":"Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache","status":"COMPLETED","sponsor":"University of Liege","startDate":"2014-09","conditions":"Chronic Cluster Headache","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Collagenase Clostridium Histolyticum"],"phase":"marketed","status":"active","brandName":"CCH administration","genericName":"CCH administration","companyName":"Charitable Union for the Research and Education of Peyronie's Disease","companyId":"charitable-union-for-the-research-and-education-of-peyronie-s-disease","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CCH (collagenase clostridium histolyticum) is an injectable enzyme that breaks down collagen in penile plaques, reducing curvature and improving erectile function in Peyronie's disease. Used for Peyronie's disease with penile curvature deformity.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}